NYSEAMERICAN:AMPE - Ampio Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.6092 +0.03 (+5.18 %)
(As of 02/17/2019 04:00 PM ET)
Previous Close$0.6092
Today's Range$0.5722 - $0.62
52-Week Range$0.35 - $3.89
Volume439,010 shs
Average Volume673,134 shs
Market Capitalization$65.01 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, an oral agent for the treatment of diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSEAMERICAN:AMPE
CUSIP03209T10
Phone+1-720-4376500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Market Cap$65.01 million
OptionableOptionable

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

When is Ampio Pharmaceuticals' next earnings date?

Ampio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Ampio Pharmaceuticals.

Has Ampio Pharmaceuticals been receiving favorable news coverage?

Media headlines about AMPE stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ampio Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Are investors shorting Ampio Pharmaceuticals?

Ampio Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 19,704,745 shares, an increase of 4.5% from the January 15th total of 18,854,705 shares. Based on an average daily trading volume, of 468,236 shares, the short-interest ratio is currently 42.1 days. Currently, 22.8% of the shares of the company are sold short. View Ampio Pharmaceuticals' Current Options Chain.

Who are some of Ampio Pharmaceuticals' key competitors?

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 67)
  • Mr. Thomas E. Chilcott III, CFO, Treasurer & Sec. (Age 51)
  • Ms. Holli Cherevka, Chief Operating Officer (Age 36)

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.11%), Northern Trust Corp (0.91%), Geode Capital Management LLC (0.81%), GSA Capital Partners LLP (0.62%), Courier Capital LLC (0.33%) and Cypress Capital Management LLC WY (0.20%). View Institutional Ownership Trends for Ampio Pharmaceuticals.

Which institutional investors are selling Ampio Pharmaceuticals stock?

AMPE stock was sold by a variety of institutional investors in the last quarter, including Cypress Capital Management LLC WY and Northern Trust Corp. View Insider Buying and Selling for Ampio Pharmaceuticals.

Which institutional investors are buying Ampio Pharmaceuticals stock?

AMPE stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Strategic Financial Services Inc , Noven Financial Group Inc., BlackRock Inc., Courier Capital LLC, Rhumbline Advisers and Geode Capital Management LLC. View Insider Buying and Selling for Ampio Pharmaceuticals.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $0.6092.

How big of a company is Ampio Pharmaceuticals?

Ampio Pharmaceuticals has a market capitalization of $65.01 million. Ampio Pharmaceuticals employs 17 workers across the globe.

What is Ampio Pharmaceuticals' official website?

The official website for Ampio Pharmaceuticals is http://ampiopharma.com/.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500.


MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEAMERICAN AMPE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel